Ovarian aging and implications for fertility female health

Minerva Endocrinologica

Volumn 37, Issue 1, 2012, Pages 41-57

  Younis, J S ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Biological markers; Fertility preservation; Oocytes; Reproductive techniques, assisted; Vitrification

Indexed keywords

FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PRASTERONE;

AGING; AUTOIMMUNITY; BLASTOCYST; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; ENDOCRINE FUNCTION TEST; FEMALE FERTILITY; FEMALE INFERTILITY; FIRST TRIMESTER PREGNANCY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLITROPIN BLOOD LEVEL; GENETIC ASSOCIATION; GENETICS; HERITABILITY; HUMAN; INFERTILITY THERAPY; LIFESTYLE; LUTEINIZING HORMONE BLOOD LEVEL; MATERNAL AGE; MENOPAUSE; OOCYTE DONATION; OVARIAN AGING; OVARIAN RESERVE; OVARY; OVARY DISEASE; OVARY FUNCTION; POLYMERASE CHAIN REACTION; POOR OVARIAN RESPONSE; PREDICTION; PREGNANCY; PREMATURE OVARIAN FAILURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REPRODUCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRASOUND; VITRIFICATION; X CHROMOSOME;

ADULT; AGING; DEHYDROEPIANDROSTERONE; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFERTILITY, FEMALE; MENOPAUSE; MIDDLE AGED; OOCYTE DONATION; OOCYTES; OVARY; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PRIMARY OVARIAN INSUFFICIENCY; REPRODUCTIVE TECHNIQUES, ASSISTED; VITRIFICATION;

EID: 84860301204     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. de Bruin JP, te Velde ER. Female reproductive ageing: concepts and consequences. In: Preservation of Fertility. Edited by Tulandi T, Gosden RG (editors). London, UK: Taylor & Francis; 2004. p. 3.
2. te Velde, ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-54. (Pubitemid 34428965)
3. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992;7:1342-6. (Pubitemid 23042150)
4. Faddy MJ. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 2000;163:43-8. (Pubitemid 30645583)
5. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod 2008;23:699-708. (Pubitemid 351651214)
6. Rosen MP, Sternfeld B, Sonya M. Schuh-Huerta SM, Reijo-Pera RA, McCullochCE et al. Antral follicle count: absence of significant midlife decline. Fertil Steril 2010;94:2182-5.
7. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011;95:736-41.
8. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocrine Reviews 2009;30;465-93.
9. Wallace WH, Kelsey TW. Human ovarian reserve from conception to menopause. PLoS One 2010;5:e8772.
10. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. Eighth Edition. Philadelphia: Lippincot Williams & Wilkins; 2011. p. 1144.
11. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nagrund G, Gianaroli L; ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-24.
12. Younis JS. Ovarian aging: latest thoughts on assessment and management. Curr Opin Obstet Gynecol 2011;23:427-34.
13. de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet 2010;376:730-8.
14. Coccia ME, Rizzello F, Mariani G, Bulleti C, Palagiano A, Scarselli G. Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod 2011;26:3000-7.
15. Almog B, Shehata F, Sheizaf B, Tan SL, Tulandi T. Effects of ovarian endometrioma on the number of oocytes retrieved for in vitro fertilization. Fertil Steril 2011;95:525-7.
16. Kitajima M, Defrère S, Dolmans MM, Colette S, Squifflet J, Van Langendonckt A et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril 2011;96:685-91.
17. Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reproduc 2007;22;1996-2005. (Pubitemid 47062769)
18. Tropeano G, Di Stasi C, Amorso S, Gualano MR, Bonomo L, Scambia G. Long-term effects of uterine fibroid embolization on ovarian reserve: a prospective cohort study. Fertil Steril 2010;94:2296-300.
19. Soto N, Iniguez G, Lopez P, Larenas G, Mujica V, Rey RA et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod 2009;24:2838-44.
20. Fréour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O et al. Ovarian reserve in young women of reproductive age with Crohn's disease. Inflamm Bowel Dis 2011 Sep 20 [Epub ahead of print].
21. Chang HH, Chen MJ, Lu MY, Chern JP, Lu CY, Yang YL et al. Iron overload is associated with low anti-müllerian hormone in women with transfusion-dependent B-thalassaemia. BJOG 2011;118;825-31.
22. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCAl mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2011;28:240-4.
23. Hendriks AEJ, Laven JSE, Valkenburg O, Fong SL, Fauser BC, de Ridder MA et al. Fertility and ovarian function in high-dose estrogen-treated tall women. J Clin Endocrin Metab 2011;96:1098-105.
24. Nejat EJ, Jindal S, Berger D, Buyuk E, Lalioti M, Pal L. Implications of blood type for ovarian reserve. Hum Reprod 2011;26:2513-7.
25. Voorhuis M, Onland-Moret NC, van der Schouw YT, Fauser BC, Broekmans FJ. Human studies on genetics of the age at natural menopause: a systematic review. Hum Reprod Update 2010;16:364-77.
26. The Evian Annual Reproduction (EVAR) Workshop Group 2010. Contemporary genetic technologies and female reproduction. Hum Reprod Update 2011;17:829-47.
27. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010;45:257-79.
28. Altmäe S, Hovatta O, Stayreus-Evers A. Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update 2011;17:813-28.
29. Nikolaou D, Templeton A. Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod 2003;18:1137-9. (Pubitemid 36740554)
30. Gleicher N, Weghofer A, Oktay K, Barad D. Do etiologies of premature ovarian aging (POA) mimic those of premature ovarian failure (POF)? Hum Reprod 2009;24:2395-400.
31. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE; OMEGA-project group. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003;18:1544-52. (Pubitemid 36840968)
32. Lawson R, El Toukhy T, Kassab A, Taylor A, Braude P, Parsons J et al. Poor response to ovulation induction is a stronger predictor of early menopause than elevated basal FSH: a life table analysis. Hum Reprod 2003;18:527-33. (Pubitemid 36329319)
33. Aboura A, Dupas C, Tachdjian G, Portnoï MF, Bourcigaux N, Dewailly D et al. Array comparative genomic hybridization profiling analysis reveals deoxyribonucleic acid copy number variations associated with premature ovarian failure. J Clin Endocrinol Metab 2009;94:4540-6.
34. McGuire MM, Bowden W, Engel NJ, Ahn HW, Kovanci E, Rajkovic A. Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure. Fertil Steril 2011;95:1595-600.
35. Broekmans FJ, Knauff EAH, te Velde ER, et al. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab 2007;18:58-65. (Pubitemid 46275460)
36. He C, Kraft P, Chasman DI, Buring JE, Chen C, Hankinson SE et al. A large-scale candidate gene association study of age at menarche and age at natural menopause. Hum Genet 2010;128:515-27.
37. Kraft P, Cox DG. Study designs for genome-wide association studies. Adv Genet 2008;60:465-504.
38. van Disseldorp J, Franke L, Eijkemans R, Broekmans F, Macklon N, Wijmenga C et al. Genome-wide analysis shows no genomic predictors of ovarian response to stimulation by exogenous FSH for IVF. Reprod Biomed Online 2011;22:382-8.
39. Mathews TJ, Hamilton BE. Mean age of mother, 1970-2000. Natl Vital Stat Rep 2002;51:1-13.
40. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685-718. (Pubitemid 44605509)
41. The Practice Committee of the American Society for Reproductive Medicine. Aging and infertility in women. Fertil Steril 2006;86S:248-52.
42. Haadsma ML, Groen H, Fidler V, Bukman A, Roeloffzen EM, Groenewoud ER, et al. The predictive value of ovarian reserve tests for spontaneous pregnancy in subfertile ovulatory women. Hum Reprod 2008;23:1800-7. (Pubitemid 352020023)
43. Moolenaar LM, Broekmans FJ, van Disseldorp J, Fauser BC, Eijkemans MJ, Hompes PG et al. Cost effectiveness of ovarian reserve testing in in vitro fertilization: a Markov decision-analytic model. Fertil Steril 2011;96:889-94.
44. Maheshwari A, Gibreel A, Bhattacharya S, Johnson NPD. Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy. Reprod Biomed Online 2009;18:717-34.
45. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83. (Pubitemid 38196508)
46. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endoc Rev 2000;21:200-14. (Pubitemid 32275595)
47. Tran ND, Cedars MI, Rosen MP. The Role of Anti-Mullerian Hormone (AMH) in Assessing Ovarian Reserve. J Clin Endocrinol Metab 2011 Sep 2011. [Epub ahead of print].
48. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS; ESHRE Special Interest Group for Reproductive Endocrinology - AMH Round Table. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 2009;24:2264-75.
49. La Marca A, Sighinolfil G, Radi D, Argento C, Baraldi E, Artenisio AC et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-30.
50. Riggs R, Kimble T, Oehninger S, Bocca S, Zhao Y, Leader B et al. Anti-Mullerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. Fertil Steril 2011;95:410-2.
51. Almog B, Shehata F, Suissa S, Holzer H, Shalom-Paz E, La Marca A et al. Age-related normograms of serum antimullerian hormone levels in a population of infertile women: a multicenter study. Fertil Steril 2011;95:2359-63.
52. La Marca A, Sighinolfi G, Giulini S, Traglia M, Argento C, Sala C et al. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles. Reprod Biomed Online 2010;21:463-9.
53. Shebl O, ebner T, Sir A, Schreier-Lechner E, Mayer RB, Tews G, Sommergruber M. Age-related distribution of basal serum AMH level in women of reproductive age and a presumably healthy cohort. Fertil Steril 2011;95:832-4.
54. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T, Fleming R et al. External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. Reproduc Biomed Online 2011;23:204-6.
55. Broer SL, Mol B, Dólleman M, Fauser BC, Broekmans FJ. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 2010;22:193-201.
56. Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353-62.
57. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S et al. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 2011;117:798-804.
58. Tehrani FR, Solaymani-Dodaran M, Azizi F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause 2009;16:797-802.
59. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-9.
60. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P et al. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reproduc 2008;23:674-8. (Pubitemid 351651205)
61. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reproduc Biomed Online 2010;20:280-5.
62. Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocriol Metab 2011;96:1336-43.
63. Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS et al. Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Müllerian hormone levels. Fertil Steril 2010;94:343-9.
64. Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T, Giannakou A et al. The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized study. Fertil Steril 2010;94:71-7.
65. Hirokawa W, Iwase A, Goto M, Takikawa S, Nagatomo Y, Nakahara T et al. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Human reproduce 2011;26:904-10.
66. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metabolism 2006;91:941-5. (Pubitemid 43357762)
67. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reproduc 2011;26:3123-9.
68. Broekmans FJ, de Ziegler D, Howies CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril 2010;94:1044-51.
69. Hendriks DJ, Kwee J, Mol BWJ, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 2007;87:764-75. (Pubitemid 46550395)
70. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M, Bergh T. Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. Fertil Steril 2011;96:594-9.
71. Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI. A lower antral follicle count is associated with infertility. Fertil Steril 2011;95:1950-4.
72. Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril 2009:91;148-56.
73. Hsu A, Amy M, Knee AB, Bell C, Cook E, Novak AL et al. Antral follicle count in clinical practice: analyzing clinical relevance. Fertil Steril 2011;95:474-9.
74. La Marca A, Spada E, Sighinolfi G, Argento C, Tirelli A, Giulini S et al. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 2011;95:684-8.
75. Almog B, Shehata F, Shalom-Paz E, Tan SL, Tulandi T. Age-related normogram for antral follicle count: McGill reference guide. Fertil Steril 2011;95:663-6.
76. Younis JS, Haddad S, Matilsky M, Radin O, Ben-Ami M. Undetectable basal ovarian stromal blood flow in infertile women is related to low ovarian reserve. Gynecol Endocrinol 2007;23:284-9. (Pubitemid 46897692)
77. Hefler LA, Grimm C, Bentz EK, Reinthaller A, Heinze G, Tempfer CB. A model for predicting age at menopause in white women. Fertil Steril 2006;85:451-4. (Pubitemid 43170922)
78. Spath MA, Feuth TB, Smits AP, Yntema HG, Braat DD, Thomas CM et al. Predictors and risk model development for menopausal age in fragile X premutation carriers. Genet Med 2011;13:643-50.
79. Lambalk CB, de Koning CH, Flett A, Van Kasteren Y, Gosden R, Homburg R. Assessment of ovarian reserve. Ovarian biopsy is not a valid method for the prediction of ovarian reserve. Hum Reprod 2004;19:1055-9. (Pubitemid 38618480)
80. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertile Steril 2011;95:170-5.
81. Broer SL, Mol BW, Hendricks D. Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705-14.
82. Van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC et al. Comparison of interand intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010:25:221-7.
83. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011;17:46-54.
84. Tan R, Pu D, Liu L, Liu J, Wu J. Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization. Fertile Steril 2011;96:905-11.
85. Verhagen TE, Hendriks DJ, Bancsi LF Mol BW, Broekmans FJ. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum Reprod Update, 2008;14:95-100. (Pubitemid 351321105)
86. Younis JS, Jadaon J, Izhaki I, Haddad S, Radin O, Bar-Ami S et al. A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. Fertil Steril 2010;94:655-61.
87. La Marca L, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online. 2011;22:341-9.
88. Al-Azemi M, Killick SR, Duffy S, Pye C, Refaat B, Hill N et al. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. Hum Reproduc 2011;26:414-22.
89. Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Human Reproduc Update 2008;14:459-84.
90. Jones KT. Meiosis in oocytes: predisposition to aneuploidy and its increased incidence with age. Hum Reprod Update 2008;14:143-8.
91. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011;26:2742-9.
92. Nardo LG, Fleming R, Howies CM, Bosch E, Hamamah S, Ubaldi FM et al. Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation. Reproduc Biomed Online 2011;23:141-8.
93. Mochtar MH, van der Veen F, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperStimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007:CD005070.
94. Alviggi C, Humaidan P, Howies CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol 2009;7:101-13.
95. Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009, 91:749-66.
96. Duffy JM, Ahmed G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2010;20:CD000099
97. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011;95:1031-6.
98. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in invitro fertilisation (IVF). Cochrane Database Syst Rev 2010;CD004379
99. Aanesen A, Nygren KG, Nylund L. Modified natural cycle IVF and mild IVF: a 10 year Swedish experience. Reprod Biomed Online 2010;20:156-62.
100. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reproduc 2007;22:980-8.
101. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 2004;15:84-90. (Pubitemid 38258332)
102. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53. (Pubitemid 41058142)
103. Hugues JN. Impact of androgen on fertility - physiological, clinical and therapeutical aspects. Reprod Biomed Online 2005;11:570-80.
104. Fabregues F, Penarrubia J, Creus M, Manau D, Casals G, Carmona F. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod 2009;24:349-59.
105. Kim CH, Colin M. Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011;95:679-83.
106. Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82-7. (Pubitemid 40991464)
107. Lee VC, Chan CC, Ng EH, Yeung WS, Ho PC. Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial. Reproduc Biomed Online 2011;23:830-8.
108. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H et al. Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 2011;9:85
109. Sipe CS, Thomas MR, Stegmann BJ, Van Voorhis BJ. Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles. Hum reproduce 2010;25:690-6.
110. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629-34.
111. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study Reprod Biol Endocrinol 2009;7:108.
112. Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 2010;8:140-4.
113. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone (DHEA) supplementation. Reprod Biomed Online 2010;21:360-5.
114. Yakin K, Urman B. DHEA as a miracle drag in the treatment of poor responders; hype or hope? Hum Reprod 2011;26:1941-4.
115. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010;25:2496-500.
116. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011;9:67.
117. Borini A, Suriano R, Barberi M, Dal Prato L, Bulletti C. Oocyte donation programs: strategy for improving results. Ann NY Acad Sci 2011;1221:27-31.
118. Boldt J. Current results with slow freezing and vitrification of the human oocyte. Reprod Biomed Online 2011;23:314-22.
119. Rienzi L, Romano S, Albricci L, Maggiulli R, Capalbo A, Baroni E et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reproduc 2010:25:66-73.
120. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011;96:277-85.